ABSTRACT
Chronic kidney disease (CKD) and congestive heart failure (CHF) are epidemiologically and pathophysiologically linked. A recent study in patients with severe CHF demonstrated that renal plasma flow was inversely correlated with pulmonary capillary wedge pressure, right atrial pressure, pulmonary pressure, and right ventricular ejection fraction. This article reviews the utility of B-type natriuretic peptide (BNP) levels in assessing cardiac function and volume status in patients with CKD and examines the safety and efficacy of BNP therapy in patients with renal insufficiency and decompensated heart failure.
Subject(s)
Heart Failure/blood , Kidney Failure, Chronic/blood , Natriuretic Peptide, Brain/blood , Animals , Comorbidity , Heart Failure/epidemiology , Hemodynamics/drug effects , Humans , Kidney/blood supply , Kidney Failure, Chronic/epidemiology , Natriuretic Agents/blood , Natriuretic Agents/pharmacology , Natriuretic Peptide, Brain/pharmacology , Prognosis , Regional Blood FlowABSTRACT
Chronic kidney disease (CKD) and congestive heart failure (CHF) are epidemiologically and pathophysiologically linked. A recent study in patients with severe CHF demonstrated that renal plasma flow was inversely correlated with pulmonary capillary wedge pressure, right atrial pressure, pulmonary pressure, and right ventricular ejection fraction. This article reviews the utility of B-type natriuretic peptide (BNP) levels in assessing cardiac function and volume status in patients with CKD and examines the safety and efficacy of BNP therapy in patients with renal insufficiency and decompensated heart failure.
